Loading...

Home
ETF
ACXP

ACXP

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

ACXP News

Acurx Pharmaceuticals to Discuss 2025 Financial Results on March 13, 2026

11h agoNewsfilter

Acurx Pharmaceuticals to Release 2025 Financial Results

11h agoPRnewswire

"New to The Street Celebrates Milestone Episode #700 Airing Today at 6:30 PM ET on Bloomberg Television"

Nov 15 2025Yahoo Finance

Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update

Nov 12 2025PRnewswire

Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens

Nov 10 2025PRnewswire

Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference

Oct 28 2025PRnewswire

Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update

Oct 27 2025PRnewswire

Acurx Receives Patent for DNA Polymerase IIIC Inhibitors from Australian Patent Office

Oct 09 2025Newsfilter

What’s Driving the Rise of Pharmaceutical Stocks XBIO, UPC, XTLB, and ACXP Today?

Oct 08 2025TipRanks

Acurx Pharmaceuticals Receives Favorable Feedback from EMA Regarding Ibezapolstat for Pediatric Use

Sep 30 2025NASDAQ.COM

Acurx Receives Favorable EMA Opinion on Pediatric Investigation Plan for Ibezapolstat in Treating C. difficile Infection in Children

Sep 30 2025Newsfilter

HC Wainwright & Co. Maintains Buy on Acurx Pharmaceuticals, Raises Price Target to $31

Aug 12 2025Benzinga

Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update

Aug 12 2025PRnewswire

Upcoming Stock Splits This Week (August 4 to August 8) – Stay Invested

Aug 04 2025TipRanks

Acurx Approves 1-for-20 Reverse Stock Split To Regain Nasdaq Compliance

Jul 31 2025NASDAQ.COM

Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split

Jul 31 2025Newsfilter